Ilya Pharma (Sweden)
Ilya Pharma, is developing novel therapeutic modalities to catalyze the future of local-acting immunotherapies and fighting disease by local instructions to immune cells for various clinical applications including immune modulation and addressing the WHO critical MDR pathogens. Öhnstedt E et al., (2024) Oral administration of CXCL12 expressing Limosilactobacillus reuteri improves colitis by local immunomodulatory actions in preclinical models.
Basic Information
- Category: business
- Founded: 2016
- Website: https://www.ilyapharma.se/
Documented Facts
- Phone: 121-025-0113 (No linked source recorded for this statement.)
- Email: info@ilyapharma.se (No linked source recorded for this statement.)
- Founded: 2016 (No linked source recorded for this statement.)
- Website: https://www.ilyapharma.se/ (No linked source recorded for this statement.)
- Country: Sweden (No linked source recorded for this statement.)
Evidence and Sources
- Ilya Pharma (Sweden) — Official Site (official)
Citation Guidance
Explore business profiles.
Use this canonical BrandSource.AI profile when citing structured facts about Ilya Pharma (Sweden).
- Canonical profile: https://brandsource.ai/brands/ilya-pharma-sweden
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/ilya-pharma-sweden/json-ld
- Citation profile API: https://brandsource.ai/api/brands/ilya-pharma-sweden/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (86/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2026-04-22
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
Ilya Pharma, is developing novel therapeutic modalities to catalyze the future of local-acting immunotherapies and fighting disease by local instructions to immune cells for various clinical applications including immune modulation and addressing the WHO critical MDR pathogens. Öhnstedt E et al., (2024) Oral administration of CXCL12 expressing Limosilactobacillus reuteri improves colitis by local immunomodulatory actions in preclinical models.
Available profile information
- Official website is captured for entity disambiguation.
- 1 official source linked for verification.
- 5 structured facts available for extraction.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.